Pediatric Hematology Oncology Articles

Expert Discusses Dramatic Larotrectinib Data in Pediatric Cancer
Ramamoorthy Nagasubramanian, MD, discusses the results of the phase I/II study of larotrectinib in pediatric patients.
Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers
Larotrectinib induced an “unprecedented” objective response rate of 93% in patients with TRK fusion–positive solid tumors.
Larotrectinib FDA Submission Completed for TRK Fusion Cancer
A rolling new drug application has been completed for larotrectinib (LOXO-101) for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.
FDA Approves Nilotinib for Pediatric CML
The FDA has approved nilotinib for the first- and second-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase. 
IKZF1 Deletions Predict Poor Prognosis in Pediatric ALL
IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL. 
Larotrectinib Update Shows Durable Responses in TRK-positive Cancers
Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor. 
Rhabdomyosarcoma Cell Origin Affects Treatment and Survival of Pediatric Patients
Mark E. Hatley, MD, discusses the research of endothelial progenitor cells in pediatric patients with rhabdomyosarcoma and how it can lead to thorough analyses of the tumor cells.
Childhood Cancer Increases Likelihood of Unemployment as Adult
One out of 6 survivors of childhood cancer was unemployed, according to results from a meta-analysis of 56 studies conducted in the United States, Canada, Asia, and Europe.
Tisagenlecleucel Responses in Pediatric ALL Sustained With Longer Follow-up
At a median follow-up of 13.1 months, tisagenlecleucel (Kymriah) induced an overall remission rate of 81% in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
FDA Puts Clinical Holds on Trials of BPX-501
The FDA has halted 4 US studies of BPX-501, a novel cellular immunotherapy for cancers and orphan inherited blood disorders, after 3 patients developed encephalopathy possibly related to treatment with BPX-501.
Publication Bottom Border
Border Publication